Standard Operating Procedure for Global Stability Testing Compliance
1) Purpose
The purpose of this SOP is to establish a systematic approach to ensure compliance with global stability testing requirements as set by major regulatory authorities such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO). This SOP provides guidelines for maintaining and demonstrating the stability of drug products throughout their shelf life to meet the varying requirements of different regulatory bodies.
2) Scope
This SOP applies to all personnel involved in stability testing, data collection, report preparation, and submission for drug products intended for global markets, including the United States, Europe, and other regions adhering to WHO guidelines.
3) Responsibilities
Stability Study Team: Responsible for conducting stability studies and ensuring data meets the requirements of the US FDA, EMA, and WHO.
Quality Control (QC) 
Regulatory Affairs Team: Responsible for ensuring that stability reports are prepared and submitted according to the requirements of each regulatory authority.
4) Procedure
4.1 Understanding Regulatory Requirements
4.1.1 Review and understand the stability testing guidelines provided by the US FDA, EMA, and WHO.
4.1.2 Ensure that
4.2 Stability Study Design
4.2.1 Design stability studies to include all required conditions (e.g., long-term, accelerated, and intermediate storage conditions) as specified by the guidelines.
4.2.2 Include multiple batches and strengths of the drug product to meet the testing requirements.
4.3 Data Collection and Analysis
4.3.1 Collect data at all required time points as per each regulatory guideline.
4.3.2 Analyze data for compliance with specifications outlined by US FDA, EMA, and WHO.
4.4 Report Preparation
4.4.1 Prepare comprehensive stability reports that meet the formatting and content requirements of each regulatory authority.
4.4.2 Include required data, discussions, conclusions, and justifications for any deviations.
4.5 Submission and Record-Keeping
4.5.1 Submit stability reports to each regulatory authority as per their specific submission guidelines.
4.5.2 Maintain records of all stability studies and related documentation for future audits and inspections.
5) Abbreviations, if any
FDA: US Food and Drug Administration
EMA: European Medicines Agency
WHO: World Health Organization
QC: Quality Control
6) Documents, if any
6.1 Regulatory guidelines from US FDA, EMA, WHO
6.2 Stability testing protocols and reports
6.3 Data collection forms
7) Reference, if any
US FDA Guidance for Industry: Stability Testing of New Drug Substances and Products Q1A(R2), EMA Guideline on Stability Testing, WHO Technical Report Series
8) SOP Version
Version 1.0